| Patient | Mumtaz Mahal |
|---|---|
| Date of birth | 1593-04-27 |
| Identifiers | MRN HR-RE006-SYN-TD; SSN (made up) 000-06-7184 |
| Document date | 1631-02-03 |
| Author | Farzana Qureshi-Lindholm, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Prenatal visit at 17 weeks; maternal-fetal medicine consultation today. [S]
Mumtaz Mahal returns at 17 weeks 2 days. The cell-free DNA result came back low risk. She has taken ferrous sulfate every other morning for four weeks but has missed about half the doses because of nausea and constipation, and she is still tired and breathless on the stairs. She takes aspirin 81 mg at bedtime without bruising or bleeding, and folic acid. She has no headache, visual change, abdominal pain, bleeding, or urinary symptoms, and has begun to feel the baby move. She saw Dr. Montgomery-Rahimi of maternal-fetal medicine this morning. [S]
| Element | Detail |
|---|---|
| Screening | Cell-free DNA low risk for trisomies 21, 18, and 13 |
| Iron | About half of the oral iron doses taken; nausea and constipation |
| Symptoms | Tired; breathless on stairs; no bleeding, headache, or pain |
| Fetal movement | First movements felt |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired by the afternoon |
| Cardiovascular | Positive | Breathless on stairs; no chest pain or palpitations |
| Gastrointestinal | Positive | Nausea and constipation since starting iron |
| Genitourinary | Negative | No bleeding, discharge, or urinary symptoms |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1631-01-06 | active | S |
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other day | One tablet every other morning with water or orange juice, apart from tea and calcium | Oral route | 1631-01-06 to 1631-02-03 | completed | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime until delivery | Oral route | 1631-01-06 | active | S |
| Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (first of two doses) | Single infusion; two doses in total, four weeks apart | Intravenous route | 1631-02-03 to 1631-02-03 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1631-02-03 | Body height | 157 | cm | S |
| 1631-02-03 | Body weight | 59.8 | kg | S |
| 1631-02-03 | Body mass index (BMI) [Ratio] | 24.3 | kg/m2 | S |
| 1631-02-03 | Systolic blood pressure | 106 | mm[Hg] | S |
| 1631-02-03 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 1631-02-03 | Heart rate | 86 | /min | S |
| 1631-02-03 | Respiratory rate | 14 | /min | S |
| 1631-02-03 | Body temperature | 36.6 | Cel | S |
| 1631-02-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1631-02-03 | Hemoglobin [Mass/volume] in Blood | 10.3 | g/dL | 10.5-15 g/dL | Low | S |
| 1631-02-03 | Ferritin [Mass/volume] in Serum or Plasma | 12 | ng/mL | 30-150 ng/mL | Low | S |
Vital signs recorded on 1631-02-03; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Pale conjunctivae; well |
| Abdomen | Fundus midway between the pubic bone and the umbilicus; non-tender |
| Fetal | Fetal heart 152 per minute by Doppler |
| Urine dipstick | Protein negative |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Fourteenth pregnancy at 37 (gravida 14, para 13), single live intrauterine pregnancy dated by ultrasound at 13 weeks 2 days; estimated due date July 12 | active | confirmed | O09.529 | S — Synthetic modern prenatal care anchored to her documented fourteenth pregnancy; the dates are synthetic. |
| Grand multiparity: thirteen previous vaginal births, no cesarean or other uterine surgery; seven living children | active | confirmed | O09.40 | S — Synthetic modern problem anchored to her documented thirteen earlier births. |
| Short interpregnancy interval: conception about five and a half months after her last birth | active | confirmed | O09.899 | S — Synthetic modern problem anchored to the documented fourteen months between her last two births. |
| Iron deficiency anemia in pregnancy: hemoglobin 10.1 g/dL, MCV 76 fL, ferritin 9 ng/mL | active | confirmed | O99.019 | S — Synthetic finding; repeated pregnancies close together deplete iron. It echoes no documented diagnosis. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and urine protein | Every prenatal visit | Completed today | 106/64 mmHg; urine protein negative |
| Examination | Fetal heart and fundal height | Every prenatal visit | Completed today | Fetal heart 152 per minute; fundus midway to the umbilicus |
| Examination | Weight gain | Every prenatal visit | Completed today | 59.8 kg, up 1.2 kg since intake |
| Laboratory | Hemoglobin and ferritin | At intake, four weeks after starting treatment, at 24 to 28 weeks, and before delivery | Completed today | Hemoglobin 10.3 g/dL and ferritin 12 ng/mL after four weeks of oral iron; intravenous iron today |
| Laboratory | Hemoglobin electrophoresis | Once, with microcytic anemia in a woman of South Asian heritage | Completed today | Normal; no thalassemia trait |
| Laboratory | First prenatal tests (blood group, antibody screen, rubella, hepatitis B, HIV, syphilis, hepatitis C, urine culture) | At the first prenatal visit | Completed today | Reviewed today: all normal or negative; RhD positive, so no anti-D is needed |
| Laboratory | Cell-free DNA screening | From 10 weeks, as she chose | Completed today | Low risk for trisomies 21, 18, and 13 |
| Medication safety | Low-dose aspirin | Daily from 12 to 16 weeks until delivery; review at every visit | Completed today | Taken nightly since 13 weeks; no bruising or bleeding |
| Referral | Maternal-fetal medicine consultation | Early in a high-risk pregnancy | Completed today | Seen today; anemia, surveillance, and delivery planning agreed |
| Imaging | Detailed anatomy scan with placental location | At 18 to 22 weeks | Due | Booked for 21 weeks |
| Laboratory | Gestational diabetes screen | Early with risk factors; again at 24 to 28 weeks | Up to date | Hemoglobin A1c 5.4 percent at intake; glucose challenge due at 24 to 28 weeks |
| Survey | Perinatal mood screen (EPDS) | Each trimester | Up to date | 8 at intake, item 10 scored 0; next in the second trimester |
| Self-management | Postpartum hemorrhage risk assessment and birth plan | At intake, in the third trimester, and on admission for birth | Up to date | Risk factors so far: grand multiparity and anemia; detailed plan due in the third trimester |
Goal progress:
Guideline basis: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Practice Bulletin No. 183: Postpartum Hemorrhage (2017); Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021); Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020); Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021)
Follow-up: Prenatal visit with the anatomy scan at 21 weeks, when the second iron dose is due. Next scheduled visit 1631-03-03: prenatal visit at 21 weeks with the anatomy scan and placental location. [S]